Merck has wrapped up its $2.7 billion acquisition of ArQule Inc., it announced Thursday.
Kenilworth-based Merck paid $20 in cash for each common share of the Burlington, Massachusetts-based biopharmaceutical company in a deal that was first announced in December.
ArQule has become a wholly owned subsidiary of Merck with the completion of the deal.
